Bone Biologics
BBLG
7 hedge funds and large institutions have $74.1K invested in Bone Biologics in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
102% more capital invested
Capital invested by funds: $36.7K → $74.1K (+$37.4K)
2.11% more ownership
Funds ownership: 0.73% → 2.84% (+2.1%)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$25K |
| 2 |
Two Sigma Investments
New York
|
+$22.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$21.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.82K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$575 |
| 2 |
CS
Clear Street
New York
|
-$385 |
BBLG Hedge Fund Activity: Q4 2025 in Review
7 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q4 2025, worth a combined $74.1K — up 102% from $36.7K a quarter earlier.
Fund positioning in BBLG was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was DRW Securities, adding an estimated $25K. The largest seller was Citigroup, exiting entirely with an estimated $575 sold.
- 7 institutional investors held Bone Biologics (BBLG) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $74.1K of Bone Biologics stock for Q4 2025, up 102% quarter-over-quarter.
- 2 funds opened new Bone Biologics positions in Q4 2025 and 2 closed out, a net change of 0 holders.
- The largest Bone Biologics buyer in Q4 2025 was DRW Securities, an estimated $25K added.
- The largest Bone Biologics seller in Q4 2025 was Citigroup, an estimated $575 sold.
Based on aggregated 13F filings for Q4 2025.